Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (388)	8/25/1999 11:22:00 PM
From: dalroi	Respond to of 1475

Rick what do you mean " I am, however, beginning to wonder if either BTRN or MEDI is the least interested in testing the special attributes of 507 as described by Dumont, Bazin and others. " TX Dalroi

To: scaram(o)uche who wrote (388)	8/25/1999 11:33:00 PM
From: LLCF	Read Replies (1) \| Respond to of 1475

<Certainly, the procedure is not intended just for siblings. > That's what I figured originally, and the question really through water on the start of the interview... of course a scientist isn't going to speculate or anything so from what I remember it was left sounding like that's the indication. Later he was then led to comment more broadly that had the sound of this changing the transplant paradigm. Rick... chance of success of this program has done what in your mind from this press release?? Doubled, tripled? The one big downside in the stock not participating IMO is that they will probably have to sell stock at some point, and I'd certainly like to see 'em see Novartis or whoever 5 million @ $10 than $5!!!!!!! darn DAK

To: scaram(o)uche who wrote (388)	8/27/1999 6:50:00 PM
From: Ilaine	Read Replies (1) \| Respond to of 1475

You might find this abstract from PubMed interesting: Lancet 1999 May 22;353(9166):1755-9 Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA. sykes@helix.mgh.harvard.edu BACKGROUND: HLA-mismatched donor bone-marrow transplantation after standard myeloablative conditioning therapy for haematological malignant disorders has been limited by severe graft-versus-host disease (GVHD) and graft failure. We tested a new approach to find out whether lymphohaemopoietic graft-versus-host reactions could occur without excessive GVHD in mixed haemopoietic chimeras produced across HLA barriers with non-myeloablative conditioning. METHODS: Five patients with refractory non-Hodgkin lymphoma underwent bone-marrow transplantation from haploidentical related donors sharing at least one HLA A, B, or DR allele on the mismatched haplotype. Conditioning included cyclophosphamide and thymic irradiation before transplantation, and antithymocyte globulin before and after transplantation. The only other GVHD prophylaxis was cyclosporin. FINDINGS: Four of five patients were evaluable and showed engraftment. Mixed haemopoietic chimerism was established, with a predominance of donor lymphoid tissue and varying degrees of myeloid chimerism. Two patients were in GVHD-free states of complete and partial clinical remission at 460 and 103 days after bone-marrow transplantation. INTERPRETATION: Mixed chimerism can be induced in adult recipients of HLA-mismatched bone-marrow transplantation by a non-myeloablative conditioning regimen. The antilymphoma responses seen in two patients suggest that allogeneic bone-marrow transplantation without myeloablative conditioning might have potent immunotherapeutic benefits. Publication Types: Clinical trial Comments: Comment in: Lancet 1999 May 22;353(9166):1725-6 PMID: 10347989, UI: 99275745